STL Archives Clindamycin
All STL articles by: Clindamycin
Truncal acne refers to AV affecting the chest and/or back, a common presentation in acne patients. This article offers guidance in clinical differentiation of truncal acne from other acneiform diseases and provides management recommendations.
Recent studies have demonstrated the role of Vitamin B Derivative (Nicotinamide), in both topical and oral forms, as a chemopreventive agent against skin cancer.
Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy". Adverse effects of such treatments are thought to be less severe, but can still be significant.
A triad approach to the treatment of acne and rosacea has been recommended. This integrated management approach includes patient education, selection of therapeutic agents, and initiation of an appropriate skin care regime. Appropriate skin care recommendations for patients with acne and rosacea will be discussed.
Hidradenitis suppurativa (HS) is a chronic disease of the follicular unit that often leads to marked impairment of quality of life. This article reviews various treatment modalities for HS including laser, surgery, retinoids, immunosuppression, biologics, and antibiotics.
An overview and update of skin treatments introduced in 2014: Quick overview of drug name, indications and regulatory status. Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Doxycycline hyclate tablets (Acticlate™), Tretinoin gel microsphere 0.08% (Retin-A Micro®) and many other drugs are covered.
Update on Apremilast tablets (Otezla®), Collagenase clostridium histolyticum for injection (Xiaflex®), Afamelanotide 16 mg subcutaneous bioresorbable implants (Scenesse®), Clindamycin phosphate 1.2% + benzoyl peroxide 3.75% gel (Onexton™), Dupilumab SC injection, Apremilast tablets (Otezla®).
Update on Brimonidine tartrate 0.33% topical gel (Mirvaso®), Mechlorethamine gel (Valchlor™), OnabotulinumtoxinA for injection (Botox® Cosmetic), Ustekinumab (Stelara®), Certolizumab pegol (Cimzia®), Infliximab (Inflectra™), Efinaconazole 10% topical solution (Jublia®)
Administration of antibiotics, often for prolonged periods, has become the standard of care for acne. The authors provide current evidence to suggest that dermatologists should consider a departure from standard operating procedure by curtailing, if not discontinuing, the routine and regular use of antibiotics for acne.
Rosacea is a common chronic skin disorder that has significant impact on the quality of life of affected individuals. Research interest has led to the development of other emerging therapies including topical ivermectin, brimonidine and oxymetazoline that hold promise for patients suffering from this condition.
Propionibacterium acnes (P. acnes) is an anaerobic bacteria implicated in the pathogenesis of acne. Current treatment guidelines offer strategies to limit the potential for resistance while achieving optimal outcome in the management of inflammatory and non-inflammatory acne.
Acne vulgaris is a common chronic inflammatory cutaneous disease involving the pilosebaceous unit. This article discusses the multifactorial nature of acne pathophysiology, therapeutics, and mechanism of action.
An overview and update of skin conditions and treatments introduced in 2010: Quick overview of drug name, indications and regulatory status. Adapalene 0.1% lotion (Differin®), Clindamycin phosphate 1.2% + tretinoin 0.025% gel (Veltin™) and many other drugs are covered.
Epidermal growth factor receptor (EGFR) inhibitors are an increasingly important treatment option for metastasized cancer in patients. We present an overview of the various cutaneous side-effects associated with EGFR inhibition and discuss their respective therapeutic options.
Benzoyl peroxide is one of the most widely used topical agents for acne. This article discusses the anti-inflammatory and comedolytic effects of benzoyl peroxide.
Young adult populations (18-25 years of age) throughout the world have latched onto the mainstream trend of body piercing. Best health care practices for these individuals involves the knowledge of proper procedural techniques, postsite care, common complications, and treatment modalities.
Topical products commonly used to treat acne include retinoids and antimicrobials, due to their effects on different components of pathogenesis. Accordingly, a fixed combination of adapalene 0.1% and benzoyl peroxide (BPO) 2.5% was developed (Epiduo™, Galderma) and was approved by the US FDA for the treatment of acne.
An overview and update of skin conditions and treatments introduced in 2008 including Methyl Aminolevulinate HCl Cream Metvixia™ + Aktilite®, Adapalene 0.1% Differin® Gel, Clindamycin Phosphate 1.2% + Benzoyl Peroxide 2.5% Acanya® Gel, Ceftobiprole Medocaril IV ZEFTERA® and other treatments
Many options exist for the treatment of rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures. The goals of therapy include reduction of papules, pustules, erythema, physical discomfort, and an improvement in quality of life.
A vast spectrum of topical anti-acne agents has emerged in response to new insights that have been gained through the understanding of disease pathophysiology and the need for clinicians to adopt an individualized therapeutic approach.
Combination therapy is a strategy of combining antibiotic treatments with other treatments with different mechanisms of action to treat acne. This has the effect of preventing or mitigating the unwanted effects of antibiotic resistant bacteria, and may confer other benefits such as lower required dosage as well.
Acne vulgaris can represent a therapeutic challenge in terms of managing ongoing symptoms and preventing scar formation. Dermatologists may now have viable new alternatives for treating all grades of acne severity that circumvent the negative side-effects associated with many conventional options.
The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the treatment of lung, pancreatic, head and neck, and colon carcinomas.
An overview and update of skin conditions and treatments introduced in 2006: Quick overview of drug name, indications and regulatory status
Skin conditions and treatments introduced in 2005 including Clindamycin Foam 1% Aluma®Skin Renewal System with FACES™, Meropenem for Injection MERREM® AstraZeneca, Moxifloxacin HCl Avelox® Bayer HealthCare Schering-Plough, Tygacycline Tygacil®, and other drugs and conditions.
Although the developing fetus was once considered protected from the outside world, we now know that it can potentially be affected by any medication given to the mother. Therapeutic options available for these patients will be discussed.
An index for drug names and conditions including Accutane®, Aczone®, Adalimumab, Agalsidase Alfa, Aldara®, Alefacept, Alesion® Dry Syrup 1%, AlloDerm®, AMEVIVE® and other drugs.
An overview and update of skin conditions and treatments introduced in 2004 including Clindamycin Foam 1% Evoclin® Connetics, Cefdinir Oral Suspension Omnicef®, Clindamycin Evoclin® Foam 1%, and other treatments.
12Page 1 of 2
LATEST: VOL 23-1, JAN 2018
Recent advances in the treatment of hereditary angioedema, particularly in the last decade has been promising. This paper reviews the mechanisms, efficacy, and adverse reactions associated with these new treatment medications.
An increasing body of research indicates that dietary change may serve as a component of therapy for certain skin conditions. This includes conditions such as acne, atopic dermatitis, aging skin, psoriasis, and rosacea. This article takes a high level overview of the role that diet may play in these conditions.
Update on drugs includes Onabotulinum-toxinA for injection (Botox® Cosmetic), Hyaluronic acid dermal filler (Restylane® Silk), Ustekinumab for SC injection (Stelara®), Golimumab for IV infusion (RSimponi Aria®), Herpes zoster vaccine (non-live recombinant, AS01B adjuvanted) suspension for IM injection (Shingrix), Brentuximab vedotin for IV infusion (Adcetris®)